Facilitating novel antitussive drug discovery.
For the past 50 years, there have been no new approved medications for the treatment of cough, which happens to be one of the top 10 symptoms for which patients seek medical care. The development of new drugs has been hindered by multiple factors: a lack of understanding of the specific mechanisms that trigger cough as a protective reflex, the mechanisms that trigger cough in various diseases, and how both differ from each other.
Another factor that has hampered the development of new antitussive medication is the lack of validated tools that allow for better assessment of cough. At PharmaLegacy, we want that to change. Together, your pipelines and our animal models hold the promise of tomorrow’s treatments.
MODELS / SERVICES
The capability to succeed:
- AAALAC and CNAS guidelines-adherent animal studies
- FDA Part 11 compliant
- 24/7 access to PharmaLegacy representatives
- Completed over 400 FDA / CFDA IND filings